Loading…
Aytu BioPharma, Inc. is projected to rise to $2.38 by 2027, a +6% move from its current price of $2.25. AYTU is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.20 | $2.25 | $2.30 | +0.05% |
| Aug 6 | $2.18 | $2.25 | $2.32 | +0.09% |
| Aug 7 | $2.17 | $2.25 | $2.34 | +0.14% |
| Aug 8 | $2.16 | $2.25 | $2.35 | +0.19% |
| Aug 9 | $2.15 | $2.26 | $2.37 | +0.23% |
| Aug 10 | $2.14 | $2.26 | $2.38 | +0.28% |
| Aug 11 | $2.13 | $2.26 | $2.39 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.13 | $2.26 | $2.39 | +0.33% |
| Week 2 | $2.09 | $2.26 | $2.46 | +0.66% |
| Week 3 | $2.06 | $2.27 | $2.51 | +0.98% |
| Week 4 | $2.03 | $2.28 | $2.56 | +1.31% |
| Week 5 | $2.01 | $2.29 | $2.60 | +1.65% |
| Week 6 | $1.99 | $2.29 | $2.64 | +1.98% |
| Week 7 | $1.98 | $2.30 | $2.68 | +2.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for ADHD, including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD.
It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc.
in March 2021. Aytu BioPharma is headquartered in Denver, Colorado.
AYTU is the ticker for Aytu BioPharma, Inc. and is currently priced at $2.16 per share. The company has a market capitalization of $23.18M and ranks 4732 by market capitalization among tracked issuers.
A major floor 13.3% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
Price is pressing into resistance (2.7% away) — a breakout level to watch.
A major ceiling 21.3% above — clearing it would confirm fresh momentum.
Key AYTU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AYTU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.13 | Buy | $2.16 | Buy |
| MA 10 | $2.15 | Buy | $2.15 | Buy |
| MA 20 | $2.17 | Buy | $2.16 | Buy |
| MA 50 | $2.18 | Buy | $2.21 | Buy |
| MA 100 | $2.36 | Sell | $2.28 | Sell |
| MA 200 | $2.37 | Sell | $2.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.90 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 107.98 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 0.45 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 56.61 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 2.14 | Buy |
| ADX (14) | 9.52 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is bearish, with RSI14 at 50. The near-term momentum is subdued and price action faces resistance near the $2.31 area.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.06 | $2.25 | $2.86 | 0% | Neutral | |
| $1.94 | $2.38 | $3.08 | +6% | Neutral | |
| $2.03 | $2.56 | $3.41 | +14% | Neutral | |
| $1.97 | $2.53 | $3.45 | +12% | Neutral | |
| $2.21 | $2.88 | $4.01 | +28% | Bullish | |
| $2.55 | $3.37 | $4.78 | +50% | Bullish | |
| $2.61 | $3.49 | $5.03 | +55% | Bullish | |
| $2.86 | $3.87 | $5.66 | +72% | Bullish | |
| $2.82 | $3.87 | $5.73 | +72% | Bullish | |
| $2.69 | $3.73 | $5.60 | +66% | Bullish | |
| $3.79 | $5.52 | $8.73 | +145% | Bullish | |
| $7.05 | $11.19 | $19.11 | +397% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.06 | $2.25 | $2.66 | +0.00% |
| September 2026 | $1.93 | $2.26 | $2.72 | +0.57% |
| October 2026 | $1.99 | $2.35 | $2.85 | +3.75% |
| November 2026 | $1.99 | $2.36 | $2.88 | +0.43% |
| December 2026 | $1.95 | $2.32 | $2.86 | -1.47% |
Click any year to see its month-by-month AYTU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, AYTU is projected to trade between $2.06 and $2.86, averaging $2.25 — a potential gain of 0% from today's $2.25. Price action looks broadly range-bound.
Aytu BioPharma, Inc.'s 2027 outlook centres on $2.38, within a $1.94 to $3.08 range. That is up +6% on the projected 2026 average. That marks a +6% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, AYTU could reach as high as $3.41, with a base case around $2.56 and support toward $2.03 — roughly +14% from $2.25. Price action looks broadly range-bound.
Expect AYTU to range from $1.97 to $3.45 through 2029. The $2.53 average target implies a +12% move from current prices. That is -1% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The AYTU price prediction for 2030 points to an average of $2.88 (low $2.21, high $4.01) — a potential gain of +28% on today's $2.25. Momentum favours further upside here.
In 2031, AYTU is projected to trade between $2.55 and $4.78, averaging $3.37 — a potential gain of +50% from today's $2.25. That is up +17% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Aytu BioPharma, Inc.'s 2032 outlook centres on $3.49, within a $2.61 to $5.03 range. That is up +3% on the projected 2031 average. That marks a +55% change versus current levels. Momentum favours further upside here.
By 2033, AYTU could reach as high as $5.66, with a base case around $3.87 and support toward $2.86 — roughly +72% from $2.25. Buyers look set to stay in control over this stretch.
Expect AYTU to range from $2.82 to $5.73 through 2034. The $3.87 average target implies a +72% move from current prices. That is 0% versus the projected 2033 average. Momentum favours further upside here.
The AYTU price prediction for 2035 points to an average of $3.73 (low $2.69, high $5.60) — a potential gain of +66% on today's $2.25. Buyers look set to stay in control over this stretch.
In 2040, AYTU is projected to trade between $3.79 and $8.73, averaging $5.52 — a potential gain of +145% from today's $2.25. That is up +48% on the projected 2035 average. Momentum favours further upside here.
Aytu BioPharma, Inc.'s 2050 outlook centres on $11.19, within a $7.05 to $19.11 range. That is up +103% on the projected 2040 average. That marks a +397% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in AYTU today (≈ 444.444444 AYTU) could be worth
$4,972.17
+$3,972.17 (+397%) by 2050 · US Dollar
Based on the average projected AYTU price of $11.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AYTUwould be worth at today's price.
$1,000 invested in AYTU on Jul 31, 2025 (≈ 409.836056 AYTU) would be worth
$922.13
-$77.87 (-7.8%) today · 0.92× · US Dollar
Based on a AYTU entry price of $2.44 vs. today's $2.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.16 | $1,041.67 | +4.2% |
| 1 month ago | $2.16 | $1,041.67 | +4.2% |
| 3 months ago | $2.61 | $862.07 | -13.8% |
| 6 months ago | $2.71 | $830.26 | -17.0% |
| 1 year ago | $2.44 | $922.13 | -7.8% |
| All time (5.0y) ago | $78.8 | $28.55 | -97.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AYTU forecast.
Our base-case forecast reaches $4.50 around 2040.
Implied market cap at $4.50: $48.3M
Looking across the multi-year forecast, the near term (2026–2029) shows neutral sentiment with averages around $2.16–$2.43. The forecast turns bullish in 2030, with an average price of $2.76 (min $2.16, max $3.76) and a 27.9 ROI estimate, followed by continued bullish momentum into the 2040s and 2050s. By 2040 the average is $5.20 (min $3.69, max $7.93) with a 140.7 ROI, and by 2050 the average is $10.62 (min $7.03, max $17.36) with a 391.5 ROI.
Tap a question to reveal the answer.
2030 average price is $2.76, with a min of $2.16 and a max of $3.76, and a projected ROI of 27.9. The sentiment is BULLISH.
The forecast shows neutral in 2026–2029, then bullish thereafter, with 2030 average $2.76 and 2050 average $10.62. The implied upside is notable but these are estimates, not guarantees.
Yes, the forecast shows an average price of $5.20 in 2040 (min $3.69, max $7.93), indicating possible reach of $5 in that window.
Current price is $2.16 and market capitalization is $23.18M.
Bearish sentiment with RSI14 at 50. The 50-day SMA is $2.19 and the 200-day SMA is $2.38, with support at $2.08 and resistance at $2.31; the 30-day range is $1.91 to $2.44.
Aytu BioPharma, Inc. Community Discussion
0Share your Aytu BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.